Sialidase Diagnostic Peptide Architecture for BV Detection

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current diagnostic methods for bacterial vaginosis (BV) lack sensitivity and specificity, with pH-based tests being inaccurate due to various vaginal conditions, and existing sialidase activity tests being insensitive.

Innovation Solution

Design and use of specifically designed peptides and indicator molecules that detect cleavage activity of sialidase enzymes, incorporating a peptide architecture with a sialyl group conjugated via a galactosyl group, which is recognized and bound by specific binding molecules after cleavage.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If pH-based diagnostic tests are used for bacterial vaginosis detection, then the tests can be performed at point of care and are simple to use, but the tests lack accuracy due to various vaginal conditions causing pH changes

Engineering Contradiction:
Improvepoint of care testingVSAvoiddiagnostic accuracy
Core Design Contradiction:
Ease of operationVSMeasurement precision

Solution Approach 1:

The invention extracts and measures the specific enzymatic activity of sialidase produced by BV-associated bacteria, rather than measuring general pH changes that can be caused by multiple vaginal conditions. This selective extraction of the diagnostic marker improves accuracy while maintaining point-of-care simplicity.

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent introduces a specific sialidase substrate as an intermediary that mediates between the bacterial enzyme activity and the detection system. This substrate-enzyme-product relationship provides a direct link to BV pathology, overcoming the non-specificity of pH measurement while keeping the test simple to perform.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If existing sialidase activity tests are used for BV detection, then the tests target the correct enzymatic marker, but the tests lack sensitivity

Engineering Contradiction:
Improvespecificity of markerVSAvoidsensitivity of detection
Core Design Contradiction:
ReliabilityVSMeasurement precision

Solution Approach 1:

The invention changes the parameters of the sialidase substrate to optimize both specificity and sensitivity. By modifying the substrate structure to include specific peptide sequences and fluorescent tags, the test achieves higher sensitivity in detecting low levels of sialidase activity while maintaining reliability through specific recognition of the enzyme's active site.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent uses a composite substrate structure combining a peptide sequence specific to sialidase with a fluorescent indicator molecule. This composite design allows the substrate to be specifically recognized by sialidase (maintaining reliability) while the fluorescent component provides sensitive detection capabilities (improving sensitivity).

Inventive Principle:
Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The proposed solution enhances the sensitivity and specificity of sialidase activity detection, allowing for more accurate diagnosis of bacterial vaginosis and potentially reducing the reliance on invasive laboratory tests.

Implementation Method 1

detecting cleavage activity of a sialidase enzyme... sialidase enzymes... that cleave exo or endo (poly-)sialic acids

Methodology Applied
Scientific EffectEnzyme catalysis: Enzyme

Data Source

PatentEP3830284B1Bacterial vaginosis diagnostic
Publication Date: 2025.02.19 MOLOGIC LTD
  • EP3830284B1 patent drawingFigure 1A~1B
  • EP3830284B1 patent drawingFigure 2A~2B
  • EP3830284B1 patent drawingFigure 3~4

AI summary

The invention provides a sialidase enzyme activity detection kit or device comprising: (i) an indicator molecule comprising a sialylated peptide and a capture site; (ii) a capture zone comprising capture molecules; and (iii) binding molecules capable of binding to the de-sialylated derivative of the indicator molecule. Also provided are methods of using the kits or devices, as well as specific indicator molecules and specific binding molecules.